PEC-Encap (encapsulated human islet cell therapy) / Vertex - LARVOL DELTA

One-Year Follow-up Safety Study in Subjects Previously Implanted With VC-01™ (clinicaltrials.gov) - P=N/A | N=51 | Completed | Sponsor: ViaCyte | Active, not recruiting ➔ Completed

Trial completion • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

VC01-103: A Study to Evaluate Safety, Engraftment, and Efficacy of VC-01 in Subjects With T1 Diabetes Mellitus (clinicaltrials.gov) - P1/2 | N=31 | Terminated | Sponsor: ViaCyte | N=70 ➔ 31 | Active, not recruiting ➔ Terminated; Insufficient functional product engraftment

Enrollment change • Trial termination • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

VC01-103: A Study to Evaluate Safety, Engraftment, and Efficacy of VC-01 in Subjects With T1 Diabetes Mellitus (clinicaltrials.gov) - P1/2 | N=70 | Active, not recruiting | Sponsor: ViaCyte | Recruiting ➔ Active, not recruiting

Enrollment closed • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

A Safety, Tolerability, and Efficacy Study of VC-01™ Combination Product in Subjects With Type I Diabetes Mellitus (clinicaltrials.gov) - P1/2; N=19; Terminated; Sponsor: ViaCyte; N=69 ➔ 19; Active, not recruiting ➔ Terminated; Insufficient functional product engraftment

Clinical • Enrollment change • Trial termination • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

"Given that viacyte has moved pec encap to phase 2, show minimal foreign body response , and cells r functional why does viacyte need Crsp?" (@Crisprtalk)

One-Year Follow-up Safety Study in Subjects Previously Implanted With VC-01™ (clinicaltrials.gov) - P=N/A; N=200; Enrolling by invitation; Sponsor: ViaCyte; Trial completion date: Nov 2021 ➔ Nov 2023; Trial primary completion date: Nov 2021 ➔ Nov 2023

Clinical • Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

A Safety, Tolerability, and Efficacy Study of VC-01™ Combination Product in Subjects With Type I Diabetes Mellitus (clinicaltrials.gov) - P1/2; N=69; Active, not recruiting; Sponsor: ViaCyte; Trial completion date: Jan 2021 ➔ Jun 2021; Trial primary completion date: Jan 2021 ➔ Jun 2021

Clinical • Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

VC01-103: A Study to Evaluate Safety, Engraftment, and Efficacy of VC-01 in Subjects With T1 Diabetes Mellitus (clinicaltrials.gov) - P1/2; N=70; Recruiting; Sponsor: ViaCyte

Clinical • New P1/2 trial • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

18F-VC701-PET and MRI in the in vivo neuroinflammation assessment of a mouse model of multiple sclerosis. (PubMed, J Neuroinflammation) - "Increase of 18F-VC701 uptake in EAE mice is strongly associated with the presence of microglia activation in the acute phase of the disease. The combined use of TSPO-PET and MRI provided complementary evidence on the ongoing disease process, thus representing an attractive new tool to investigate neuronal damage and neuroinflammation at preclinical levels."

Journal • Preclinical • Biosimilar • CNS Disorders • Immunology • Multiple Sclerosis

A natural solution to photoprotection and isolation of the potent polyene antibiotic, marinomycin A. (PubMed, Chem Sci) - "The SpEC encapsulation of the marinomycin A dramatically increases the half-life of the polyene macrodiolide to the direct exposure to UV radiation by several orders of magnitude, thereby making this a potentially useful strategy for other light sensitive bioactive agents. In addition, we report that the SpECs can also be used to selectively extract culture broths that contain the marinomycins, which provides a significantly higher recovery than with conventional XAD resins and provides concomitant photoprotection."

Journal